Last reviewed · How we verify

Amikellin — Competitive Intelligence Brief

Amikellin (KHELLIN) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: khellin. Area: Metabolic.

phase 2 khellin Cytochrome P450 1A1 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Amikellin (KHELLIN). Khellin works by inhibiting the Cytochrome P450 1A1 enzyme, which plays a role in the metabolism of certain substances in the body.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Amikellin TARGET KHELLIN phase 2 khellin Cytochrome P450 1A1
Heraclin BERGAPTEN phase 3 bergapten Taste receptor type 2 member 10, Cytochrome P450 1A1, Amine oxidase [flavin-containing] A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (khellin class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amikellin — Competitive Intelligence Brief. https://druglandscape.com/ci/khellin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing